First clinical results for the treatment of central centrifugal cicatricial alopecia in Black women introduce more inclusive solutions.
REVIAN Inc. revealed positive outcomes for the use of Revian Red System to treat patients with Central Centrifugal Cicatricial Alopecia (CCCA).1 Researchers at Wake Forest University School of Medicine in Salem-West, North Carolina, presented their findings regarding CCCA and the Revian Red System at the virtual 2021 Society for Investigative Dermatology annual meeting.
CCCA predominantly affects Black women and causes scarring hair loss. CCCA is believed to have environmental, genetic, and inflammatory factors. Other forms of high-level LED light or laser therapy are harsh on Black women’s skin and can cause additional scarring or hyperpigmentation. 2 Adverse events from laser treatments can also change skin texture. Instead of laser treatments, low-level light therapy is more inclusive.
"To our knowledge, this is the first study evaluating the use of low-level light therapy for CCCA management and we were excited to partner with the Revian team to evaluate a treatment for this devastating condition", said Amy McMichael MD, chair and professor of dermatology at Wake Forest University School of Medicine in Salem-West, North Carolina. "In my opinion, the Revian Red System is showing promising results for a complex disease for which we have no treatment options."
The Revian Red System uses a patented combination of two LED lights to stimulate the production and release of nitric oxide (NO), increase blood flow, reduce inflammation, and inhibit DHT production which provides the best environment for hair growth. Black women with a biopsy-proven diagnosis of stage II-IV CCCA participated in the prospective clinical trial conducted by the Center for Dermatology Research, Department of Dermatology at the Wake Forest University School of Medicine. 6 patients of approximately 53.4 years old participated in the study for 6 months. Participants experienced various disease severities for approximately 12 months before beginning treatment.
The results indicated:
The clinical study’s positive results encourage more accurate diagnoses and treatments of CCCA in Black women.